Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide

Microbes and Infection

Volumn 9, Issue 11, 2007, Pages 1299-1306

  Foo, Damian Guang Wei ^a   Alonso, Sylvie ^a   Chow, Vincent Tak Kwong ^a   Poh, Chit Laa ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Enterovirus 71; Passive protection; Synthetic peptide; VP1 capsid protein

Indexed keywords

NEUTRALIZING ANTIBODY; SYNTHETIC PEPTIDE; SYNTHETIC PEPTIDE SP70; SYNTHETIC PEPTIDE SP70 ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; ENTEROVIRUS 71; ENTEROVIRUS INFECTION; FEMALE; HISTOLOGY; IN VIVO STUDY; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTECTION; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL;

ANIMALS; ANTIBODIES, VIRAL; ENTEROVIRUS A, HUMAN; ENTEROVIRUS INFECTIONS; EPITOPES; IMMUNIZATION, PASSIVE; INTESTINE, SMALL; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; VACCINES, SYNTHETIC;

HUMAN ENTEROVIRUS 71; MIRIDAE; MUS;

EID: 35148834304     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2007.06.002     Document Type: Article

References (29)

1. Mizuta K., Abiko C., Murata T., Matsuzaki Y., Itagaki T., Sanjoh K., Sakamoto M., Hongo S., Murayama S., and Hayasaka K. Frequent importation of enterovirus 71 from surrounding countries into the local community of Yamagata, Japan, between 1998 and 2003. J. Clin. Microbiol. 43 (2005) 6171-6175
2. Wong K.T., Lum L.C., and Lam S.K. Enterovirus 71 infection and neurologic complications. N. Engl. J. Med 342 (2000) 356-358
3. Lum L.C., Wong K.T., Lam S.K., Chua K.B., Goh A.Y., Lim W.L., Ong B.B., Paul G., AbuBakar S., and Lambert M. Fatal enterovirus 71 encephalomyelitis. J. Pediatr. 133 (1998) 795-798
4. Chang L.Y., Lee C.Y., Kao C.L., Fang T.Y., Lu C.Y., Lee P.I., and Huang L.M. Hand, foot and mouth disease complicated with central nervous system involvement in Taiwan in 1980-1981. J. Formos. Med. Assoc. 106 (2007) 173-176
5. McMinn P.C. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS. Microbiol. Rev. 26 (2002) 91-107
6. Chang L.Y., Lin T.Y., and Huang Y.C. Fulminant neurogenic pulmonary oedema with hand, foot and mouth disease. Lancet 352 (1998) 367-368
7. Ho M., Chen E.R., Hsu K.H., Twu S.J., Chen K.T., Tsai S.F., Wang J.R., and Shih S.R. An epidemic of enterovirus 71 infection in Taiwan. N. Engl. J. Med. 341 (1999) 929-935
8. Wang S.M., Liu C.C., Tseng H.W., Wang J.R., Huang C.C., Chen Y.J., Yang Y.J., Lin S.J., and Yeh T.F. Clinical spectrum of enterovirus 71 infection in children in southern Taiwan, with an emphasis on neurological complications. Clin. Infect. Dis. 29 (1999) 184-190
9. Mateu M.G. Antibody recognition of picornaviruses and escape from neutralization: a structural view. Virus Res. 38 (1995) 1-24
10. Ruekert R.R. In: Fields B.N., Knipe D.M., Howley P.M., et al. (Eds). Picornaviridae: The Viruses and Their Replication. third ed. Fields Virology (1996), Lippincott-Raven Publishers, Philadelphia 609-640
11. Mendelsohn C., Wimmer E., and Racaniello V.R. Cellular receptors for poliovirus: molecular cloning, nucleotide sequence and expression of a new member of the immunoglobulin super family. Cell 56 (1989) 855-865
12. Bergelson J.M., Sepley M.P., Chan B.M.C., Heinler M.E., and Finberg R.N. Identification of the antigen VLA-2 as a receptor for echovirus 1. Science 255 (1992) 1718-1720
13. Greve J.M., Davis G., Meyer A.M., Forte C.P., Yost S.C., Marlor C.W., Kamarck M.E., and McClelland A. The major human rhinovirus receptor is ICAM-1. Cell 56 (1989) 839-847
14. Van Wezel A.L., Van der Marel P., Hazendonk T.G., Boer Bak V., and Henneke M.A. Antigenicity and immunogenicity of poliovirus capsid proteins. Dev. Biol. Stand. 55 (1983) 209-215
15. Moore D.M., and Cowan K.M. Effect of trypsin and chymotrypsin on the polypeptides of large and small plaque variants of foot-and-mouth disease virus: relationship to specific antigenicity and infectivity. J. Gen. Virol. 41 (1978) 549-562
16. Yu C.K., Cheng C.C., Cheng C.L., Wang J.R., Liu C.C., Yan J.J., and Su I.J. Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice. J. Biomed. Sci. 7 (2000) 523-528
17. Wu C.N., Lin Y.C., Fann C., Liao N.S., Shih S.R., and Ho M.S. Protection against enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 20 (2001) 895-904
18. Foo D.G.W., Alonso S., Phoon M.C., Ramachandran N.P., Chow V.T.K., and Poh C.L. Identification of neutralizing linear epitopes from the VP1 capsid protein of enterovirus 71 using synthetic peptides. Virus Res. 125 (2007) 61-68
19. Reed L.J., and Muench H. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27 (1938) 4931-4937
20. Tan E.L., Chow V.T.K., Kumarasinghe G., Tze R.P.L., MacKay I.M., Sloots T.P., and Poh C.L. Specific detection of enterovirus 71 directly from clinical specimens using real-time RT-PCR hybridization probe assay. Mol. Cell. Probes 20 (2006) 135-140
21. Kimura-Kuroda J., and Yasui K. Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies. J. Immunol. 141 (1988) 3606-3610
22. Huang Y.C., Lin T.Y., Lin Y.J., Lien R.I., and Chou Y.H. Prophylaxis of intravenous immunoglobulin and acyclovir in perinatal varicella. Eur. J. Pediatr. 160 (2001) 91-94
23. Geller T.J., and Condie D. A case of protracted coxsackie virus meningoencephalitis in a marginally immunodeficient child treated successfully with intravenous immunoglobulin. J. Neurol. Sci. 129 (1995) 131-133
24. Tan C.S., and Cardosa M.J. High-titred neutralizing antibodies to human enterovirus 71 preferentially bind to the N-terminal portion of the capsid protein VP1. Arch. Virol. (2007)
25. Chiu C.H., Chu C., He C.C., and Lin T.Y. Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microbes Infect. 8 (2006) 1-8
26. Haro I., and Gomara M.J. Design of synthetic peptide constructs for the vaccine development against viral infections. Curr. Protein Pept. Sci. 5 (2004) 425-433
27. Rosenthal K.S., and Zimmerman D.H. Vaccines: all things considered. Clin. Vaccine Immunol. 13 (2006) 821-829
28. Hunt A.R., Frederickson S., Hinkel C., Bowdish K.S., and Roehrig J.T. A humanized murine monoclonal antibody protects mice either before or after challenge with virulent Venezuelan equine encephalomyelitis virus. J. Gen. Virol. 87 (2006) 2467-2476
29. Fuller H., and Del Mar C. Immunoglobulin treatment for respiratory syncytial virus infection. Cochrane Database Syst. Rev. 4 (2006) CD004883